
International • New Delhi • 9 November 2026
ANTI-CANCER-DRUG-PRICE-CUTS-INDIA-NOVEMBER-2026
In a significant move aimed at making cancer treatment more affordable, revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer drug formulations across 121 drugs have come into effect across India from November 9, 2026. The price revisions are projected to provide annual savings of approximately ₹3,540 crore to consumers, offering financial relief to thousands of cancer patients and their families.
The initiative is expected to ease the financial burden associated with cancer treatment, which often involves prolonged medication, regular medical consultations and substantial healthcare expenditure.
Revised Prices to Bring Relief to Patients
Cancer treatment remains one of the most financially demanding healthcare challenges for patients and their families. The high cost of essential medicines, particularly during long-term treatment, can place considerable pressure on household budgets.
With the revised MRPs now effective, patients purchasing the covered anti-cancer formulations are expected to benefit from reduced medicine costs. The projected annual savings of ₹3,540 crore underline the potential impact of the price revision on healthcare affordability.
The move is particularly significant for patients requiring continuous medication, as even a reduction in the cost of individual formulations can translate into considerable savings over the course of treatment.
Focus on Affordable Cancer Care
The revised prices form part of efforts to improve access to essential medicines and strengthen affordability within India’s healthcare system.
The National Pharmaceutical Pricing Authority (NPPA), which oversees pharmaceutical pricing in the country, has published revised price information for anti-cancer medicines under its trade margin rationalisation initiative.
The revised pricing is expected to support patients in accessing necessary medicines without facing the same level of financial pressure associated with high treatment costs.
A Step Towards Reducing the Cost of Cancer Treatment
The implementation of revised MRPs marks an important development in India’s efforts to make cancer care more accessible.
While the actual savings for individual patients will depend on the medicines prescribed and their treatment requirements, the projected annual reduction in expenditure represents a significant step towards easing the economic burden of cancer.
The latest revision is expected to benefit patients, caregivers and families dealing with the financial challenges of cancer treatment, reinforcing the importance of affordable and accessible healthcare.
Source: National Pharmaceutical Pricing Authority (NPPA)



